We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+15.31%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$51.8M
AUM Growth
+$4.44M
Cap. Flow
-$659K
Cap. Flow %
-1.27%
Top 10 Hldgs %
97.02%
Holding
55
New
45
Increased
2
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$5.02M
2
GSK icon
GSK
GSK
+$5M
3
CAH icon
Cardinal Health
CAH
+$2.28M
4
UTMD icon
Utah Medical Products
UTMD
+$730K
5
UNH icon
UnitedHealth
UNH
+$201K

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$4.42M
2
GILD icon
Gilead Sciences
GILD
+$3.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$2.49M
4
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$2.26M
5
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.13M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTMD icon
1
Utah Medical Products
UTMD
$221M
$9.45M 18.25%
94,000
+8,000
+9% +$730K
CAH icon
2
Cardinal Health
CAH
$55.4B
$7.69M 14.84%
100,000
+30,000
+43% +$2.28M
CI icon
3
Cigna
CI
$72.9B
$5.3M 10.24%
16,000
-1,000
-6% -$316K
VTRS icon
4
Viatris
VTRS
$19.2B
$5.29M 10.21%
475,000
-5,000
-1% -$52.3K
GSK icon
5
GSK
GSK
$104B
$5.27M 10.18%
+150,000
New +$5M
GILD icon
6
Gilead Sciences
GILD
$162B
$5.22M 10.07%
60,760
-44,240
-42% -$3.5M
CVS icon
7
CVS Health
CVS
$123B
$4.85M 9.36%
+52,000
New +$5.02M
BMY icon
8
Bristol-Myers Squibb
BMY
$131B
$4.68M 9.03%
65,000
-33,000
-34% -$2.49M
ZVRA icon
9
Zevra Therapeutics
ZVRA
$699M
$1.51M 2.92%
330,000
-420,000
-56% -$2.13M
AUPH icon
10
Aurinia Pharmaceuticals
AUPH
$2.1B
$994K 1.92%
230,000
– –
UNH icon
11
UnitedHealth
UNH
$367B
$201K 0.39%
+379
New +$201K
ABBV icon
12
AbbVie
ABBV
$430B
$131K 0.25%
+811
New +$124K
MRK icon
13
Merck
MRK
$317B
$123K 0.24%
+1,110
New +$113K
LLY icon
14
Eli Lilly
LLY
$1.06T
$123K 0.24%
+335
New +$119K
TMO icon
15
Thermo Fisher Scientific
TMO
$213B
$121K 0.23%
+220
New +$117K
REGN icon
16
Regeneron Pharmaceuticals
REGN
$79B
$67.1K 0.13%
+93
New +$68.6K
PFE icon
17
Pfizer
PFE
$149B
$62.5K 0.12%
+1,220
New +$58.5K
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$123B
$62.4K 0.12%
+216
New +$65.8K
COR icon
19
Cencora
COR
$62.8B
$51.2K 0.1%
+309
New +$48.8K
BSX icon
20
Boston Scientific
BSX
$71.1B
$49.1K 0.09%
+1,061
New +$45.9K
SYK icon
21
Stryker
SYK
$129B
$48.4K 0.09%
+198
New +$44.9K
IQV icon
22
IQVIA
IQV
$38.1B
$44.1K 0.09%
+215
New +$43.6K
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.8B
$42.8K 0.08%
+414
New +$38.9K
DXCM icon
24
DexCom
DXCM
$31.3B
$33.9K 0.07%
+299
New +$32.8K
MRNA icon
25
Moderna
MRNA
$21.5B
$33.6K 0.06%
+187
New +$30.6K
1
2 3

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return

HealthInvest Partners's Q4 2022 Portfolio in Review

As of Q4 2022, HealthInvest Partners held 55 positions worth $51.8M, up 9.4% from $47.3M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

HealthInvest Partners's Q4 2022 filing shows 45 new, 2 increased, 5 reduced and 2 closed positions. Its largest new stake was CVS Health: 52,000 shares worth $4.85M. The largest sale was McKesson, an estimated $4.42M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • HealthInvest Partners's largest Q4 2022 buy was CVS Health: 52,000 shares worth $4.85M.
  • HealthInvest Partners added most to Cardinal Health in Q4 2022, an estimated $2.28M increase.
  • HealthInvest Partners's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $3.5M.
  • HealthInvest Partners fully exited McKesson in Q4 2022, selling an estimated $4.42M.
  • HealthInvest Partners's ten largest holdings make up 97% of its $51.8M portfolio in Q4 2022.
  • HealthInvest Partners opened 45 new positions and closed 2 in Q4 2022.
  • HealthInvest Partners's portfolio value rose 9.4% quarter-over-quarter to $51.8M.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.